Edition:
United Kingdom

Ablynx NV (ABLX.OQ)

ABLX.OQ on NASDAQ Stock Exchange Global Select Market

43.80USD
8:59pm GMT
Change (% chg)

$2.17 (+5.21%)
Prev Close
$41.63
Open
$42.90
Day's High
$44.28
Day's Low
$42.72
Volume
155,543
Avg. Vol
--
52-wk High
$45.58
52-wk Low
$17.75

Chart for

About

Ablynx NV is a Belgium-based biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx NV has more than 30 proprietary and... (more)

Overall

Beta: 1.59
Market Cap(Mil.): €987.62
Shares Outstanding(Mil.): 61.42
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 85.70 16.58
EPS (TTM): -- -- --
ROI: -- 3.19 10.60
ROE: -- 4.52 14.19

LIVE MARKETS-Closing snapshot: European stocks see a bright start to the week

Jan 22 Welcome to the home for real time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Julien Ponthus. Reach him on Messenger to share your thoughts on market moves: julien.ponthus.thomsonreuters.com@reuters.net CLOSING SNAPSHOT: A BRIGHT START TO THE WEEK (1709 GMT) European stocks have closed in positive territory, while a stronger pound hampered the FTSE 100. Could this be gearing up to be week four of gains? I

5:09pm GMT

Biotech M&A takes off as Sanofi and Celgene spend $20 billion

Biotech deal activity exploded on Monday with French drugmaker Sanofi and U.S.-based Celgene spending a combined total of more than $20 billion (14.39 billion pounds) to add new products for haemophilia and cancer to their medicine cabinets. | Video

4:23pm GMT

Biotech M&A takes off as Sanofi and Celgene spend $20 billion

Biotech deal activity exploded on Monday with French drugmaker Sanofi and U.S.-based Celgene spending a combined total of more than $20 billion to add new products for hemophilia and cancer to their medicine cabinets. | Video

4:09pm GMT

WRAPUP 2-Biotech M&A takes off as Sanofi and Celgene spend $20 billion

* Large drugmakers scour for products from smaller biotechs (Adds detail on gains in other biotech shares)

4:03pm GMT

LIVE MARKETS-Preparing for a change in style

Jan 22 Welcome to the home for real time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Julien Ponthus. Reach him on Messenger to share your thoughts on market moves: julien.ponthus.thomsonreuters.com@reuters.net PREPARING FOR A CHANGE IN STYLE (1556 GMT) As we mentioned earlier, JP Morgan recommends a change of style, out of Growth and into Value stocks in order to guard against a rising bond yield environment

3:56pm GMT

Sanofi digs deep to buy U.S. hemophilia group Bioverativ for $11.6 billion

PARIS French healthcare group Sanofi has agreed to buy U.S. hemophilia specialist Bioverativ for $11.6 billion, its biggest deal for seven years and a major play to strengthen its presence in treatments for rare diseases. | Video

3:47pm GMT

UPDATE 5-Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 bln

* Shares in Sanofi down 4 percent (Updates shares, adds links to Breakingviews and other stories)

3:45pm GMT

LIVE MARKETS-Hold the phone: deal talk boosts telecoms

Jan 22 Welcome to the home for real time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Julien Ponthus. Reach him on Messenger to share your thoughts on market moves: julien.ponthus.thomsonreuters.com@reuters.net HOLD THE PHONE: DEAL TALK BOOSTS TELECOMS (1530 GMT) Top of the sector leaderboard as we head towards the close are telecoms stocks, up 1.6 percent, after a report in Le Monde that Orange and Deutsch

3:36pm GMT

LIVE MARKETS-Ocado: Feels like a squeeze

Jan 22 Welcome to the home for real time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Julien Ponthus. Reach him on Messenger to share your thoughts on market moves: julien.ponthus.thomsonreuters.com@reuters.net OCADO: FEELS LIKE A SQUEEZE (1515 GMT) According to Jefferies, it's unlikely that the surge in Ocado shares is due to the fundamentals of the Sobey deal, which will allow Canada's second largest food su

3:15pm GMT

LIVE MARKETS-Rising rates and utilities, it's not necessarily all that bad

Jan 22 Welcome to the home for real time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Julien Ponthus. Reach him on Messenger to share your thoughts on market moves: julien.ponthus.thomsonreuters.com@reuters.net RISING RATES AND UTILITIES, IT'S NOT NECESSARILY ALL THAT BAD (1423 GMT) You would think that with monetary normalisation on the agenda and rising rates on their way, there isn't much of a case for inve

2:23pm GMT

Earnings vs. Estimates